Patents by Inventor Pei Zhou

Pei Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190200948
    Abstract: The present disclosure is related to systems and methods for monitoring a medical device. The medical device may include a tube configured to generate radiation rays and a detector configured to receive radiation rays emitted from the tube. The tube may include an anode target and a filament. The detector may include a plurality of detecting units. The method may include obtaining imaging data acquired by the detector via detecting radiation rays emitted from the tube. The method may also include determining a first feature parameter associated with the radiation rays based on the imaging data. The method may further include monitoring the medical device based on the first feature parameter associated with the radiation rays.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 4, 2019
    Applicant: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventors: Tao HE, Jiawen ZHOU, Zhouyuan FAN, Bing LI, Pei ZHOU
  • Publication number: 20190169114
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20190166208
    Abstract: Cognitively detecting cloud services and their associated status of a Virtual Machine and/or Container in a cloud platform to predict availability of cloud services preferably including the status of the services, a service object health map, and a service health status. The outputs are preferably sent to a user for feedback, which is sent back to the cognitive service.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 30, 2019
    Inventors: Hui Qing Shi, Wei Wang, Yi Bin Wang, Yuan Yuan, Ya Pei Zhou
  • Publication number: 20190098561
    Abstract: Embodiments of this application provide an information transmission method, a network device, and a user equipment. The method provided in this application includes: sending, by a network device, a broadcast frame that includes first duration information and second duration information that are of A-BFT (Association Beamforming Training); receiving a frame sent by a first user equipment in a timeslot randomly selected from a first time range; and receiving a frame sent by a second user equipment in a timeslot randomly selected from a second time range. According to the embodiments of this application, beamforming training efficiency can be improved.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 28, 2019
    Inventors: Pei ZHOU, Yan LONG, Xiao HAN, Yingpei LIN
  • Patent number: 10189786
    Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignees: DUKE UNIVERSITY, UNIVERSITY OF NORTH CAROLINA
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Patent number: 9908851
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: March 6, 2018
    Assignees: Duke University, University of North Carolina Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20170349544
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 21, 2017
    Publication date: December 7, 2017
    Inventors: Pei Zhou, Eric J. Toone
  • Patent number: 9738604
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: August 22, 2017
    Assignee: Duke University
    Inventors: Pei Zhou, Eric J. Toone
  • Publication number: 20160221934
    Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: August 4, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200673
    Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200682
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20130231323
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: September 6, 2011
    Publication date: September 5, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Pei Zhou, Eric J. Toone
  • Publication number: 20120020991
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Application
    Filed: October 7, 2011
    Publication date: January 26, 2012
    Applicant: BioZyme, Inc.
    Inventors: Marcia Moss, Pei Zhou
  • Patent number: 8034783
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: October 11, 2011
    Assignees: Biozyme, Inc., Duke University
    Inventors: Marcia Moss, Pei Zhou
  • Publication number: 20100081620
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 1, 2010
    Inventors: Marcia Moss, Pei Zhou
  • Patent number: 7638301
    Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 29, 2009
    Assignees: BioZyme, Inc., Duke University
    Inventors: Marcia Moss, Pei Zhou
  • Patent number: D823000
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: July 17, 2018
    Assignee: COLGATE-PALMOLIVE COMPANY
    Inventors: Daniel Wainless, Douglas Hohlbein, Douglas Henderson, Jiunnhaur Lim, Jiantao Wang, Pei Zhou
  • Patent number: D828035
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Daniel Wainless, Douglas Hohlbein, Douglas Henderson, Jiunnhaur Lim, Jiantao Wang, Pei Zhou
  • Patent number: D837527
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Daniel Wainless, Douglas Hohlbein, Douglas Henderson, Jiunnhaur Lim, Jiantao Wang, Pei Zhou, Thuanchong Tan, Pengyang Fu
  • Patent number: D853732
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 16, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Daniel Wainless, Douglas Hohlbein, Douglas Henderson, Jiunnhaur Lim, Jiantao Wang, Pei Zhou, Thuanchong Tan, Pengyang Fu